Cargando…
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
BACKGROUND: Early reports on patients with cancer and COVID-19 have suggested a high mortality rate compared with the general population. Patients with thoracic malignancies are thought to be particularly susceptible to COVID-19 given their older age, smoking habits, and pre-existing cardiopulmonary...
Ejemplares similares
-
TERAVOLT: Thoracic Cancers International COVID-19 Collaboration
por: Whisenant, Jennifer G., et al.
Publicado: (2020) -
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience
por: Trama, Annalisa, et al.
Publicado: (2020) -
MA12.03 A Thoracic Cancers International COVID 19 Collaboration Survey on Patients’ Perceptions of COVID-19 (Teravolt-Paper)
por: Wong, S., et al.
Publicado: (2021) -
P09.18 COVID-19 Outcomes in Patients With Thoracic Malignancies According to Gender and Ethnicity (TERAVOLT)
por: Whisenant, J., et al.
Publicado: (2021) -
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry
por: Whisenant, Jennifer G., et al.
Publicado: (2022)